Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 440 participants.

Also called NCT03072082

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 440 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03072082
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03072082. Randomized; double masking; primary purpose treatment. Start 2017-06 (anticipated); primary completion 2018-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization
Intervention (Drug)
Danlou Tablet
Intervention (Drug)
DanLou Tablet placebo
Intervention (Drug)
Aspirin Enteric-coated Tablets
Intervention (Drug)
Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Intervention (Drug)
Atorvastatin calcium
Intervention (Drug)
Isosorbide Mononitrate Tab 20 MG
Intervention (Drug)
Metoprolol Tartrate Tab 25 MG
Intervention (Drug)
Trimetazidine Dihydrochloride Tablets
Lead sponsor
Jun Li (class: other)
Collaborator
China Academy of Chinese Medical Sciences (class: other)

Record details

Record id
cardio:ct-nct03072082
Content hash
f0241da0c1f96d96ffdcf7d603a4ea91db44a7e8c2b582a552d6bd83094355e6